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Purpose: Determining the role of DYNC2H1 variants in
nonsyndromic inherited retinal disease (IRD).
Methods: Genome and exome sequencing were performed for five
unrelated cases of IRD with no identified variant. In vitro assays
were developed to validate the variants identified (fibroblast assay,
induced pluripotent stem cell [iPSC] derived retinal organoids, and
a dynein motility assay).
Results: Four novel DYNC2H1 variants (V1, g.103327020_10332
7021dup; V2, g.103055779A>T; V3, g.103112272C>G; V4,
g.103070104A>C) and one previously reported variant (V5,
g.103339363T>G) were identified. In proband 1 (V1/V2), V1 was
predicted to introduce a premature termination codon (PTC),
whereas V2 disrupted the exon 41 splice donor site causing
incomplete skipping of exon 41. V1 and V2 impaired dynein-2
motility in vitro and perturbed IFT88 distribution within cilia. V3,
homozygous in probands 2–4, is predicted to cause a PTC in a retina-
predominant transcript. Analysis of retinal organoids showed that this
new transcript expression increased with organoid differentiation. V4,
a novel missense variant, was in trans with V5, previously associated
with Jeune asphyxiating thoracic dystrophy (JATD).
Conclusion: The DYNC2H1 variants discussed herein were either
hypomorphic or affecting a retina-predominant transcript and
caused nonsyndromic IRD. Dynein variants, specifically
DYNC2H1 variants are reported as a cause of non syndromic IRD.
Genetics in Medicine (2020) https://doi.org/10.1038/s41436-020-
0915-1
Keywords: inherited retinal disease (IRD); retinitis pigmentosa
(RP); primary cilia; DYNC2H1; intraflagellar transport (IFT)
INTRODUCTION
Inherited retinal diseases (IRDs) are a clinically and
genetically heterogeneous group of disorders that often lead
to photoreceptor degeneration.1 Technological advances
have resulted in the identification of over 300 IRD genes
to date (https://sph.uth.edu/retnet/).2 Next-generation
sequencing of IRD gene panels is now commonly used for
clinical genetic testing and the current yield is around 66%.3
When no pathogenic variant is identified, exome sequencing
or genome sequencing may help uncover the variants missed
by panel-based screening. As the common IRD variants have
largely been identified, exome sequencing or genome
sequencing identify rare variants that require functional
validation.
Biallelic variants in the cilia gene DYNC2H1 have been
associated with two severe ciliopathies: Jeune asphyxiating
thoracic dystrophy (JATD, MIM 613091) and short-rib
polydactyly (SRP, MIM 613091) with only four documented
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cases of associated complex early retinal degeneration at ages
2 months, and 2, 5, and 11 years old.4–6 DYNC2H1 encodes
the primary subunit of dynein-2, the motor protein that
drives ciliary retrograde intraflagellar transport (IFT).7 IFT is
an important bidirectional transport of multisubunit protein
complexes (IFT particles) along the axonemal microtubules
that is essential to normal cilia assembly, function, and
maintenance.8,9 Hence, DYNC2H1 mutants show ciliary
accumulation of IFT complex proteins, such as IFT88.4,10
The IFT process is important to the photoreceptor, where
the connecting cilium is the major transit conduit between
the inner segment and the outer segment where light is
processed.11,12 A large portion of IRD genes encode for
ciliary proteins.13–15 Defects in IFT have an impact on
photoreceptor function and survival because poor protein
transport affects outer segment health leading to photo-
receptor cell death, IRD, and blindness.16 In zebrafish,
variants in DYNC2H1 cause abnormal photoreceptor devel-
opment.11 No mutant mice retina phenotype has been
documented.
Using exome sequencing and genome sequencing, we
document four novel DYNC2H1 pathogenic variants,
and one variant previously reported in five unrelated
cases of nonsyndromic progressive IRD. All identified
variants affect either a retina-predominant transcript
or are hypomorphic, suggesting a basis for a nonsyndromic
retinal phenotype. Here we discuss the discovery and
validation approaches used, as well as propose novel
disease-causing mechanisms for DYNC2H1 in nonsyndro-
mic IRD.
MATERIALS AND METHODS
Full methodological details
Complete methods and any associated references can be
found in Supplementary Methods.
Patient recruitment and clinical evaluation
Patients were recruited and evaluated at different institutions,
in different countries (Table 1, Fig. 1, Supplementary Results).
Phenotypes were documented retrospectively through chart
review when possible or by patient self-reporting. When
possible, examinations were validated with visual field testing,
fundus photography, fundus autofluorescence, optical coher-
ence tomography (OCT), and chest/hands X-rays.
Ethics statement
All studies conducted were approved by the ethics review
boards of the participating institutions and met the Tenets of
the Declaration of Helsinki. Informed consent and consent to
publish patient photos was obtained from all subjects.
Exome sequencing and genome sequencing identified
DYNC2H1 variants as a cause of nonsyndromic IRD
To identify the underlying genetic cause of retinal disease,
genome sequencing of genomic DNA was used for probands 1,
3, and 4, while exome sequencing was used for probands 2 and
5 (Supplementary Methods, Fig. S1). Although the details of
each approach varied between the five study groups, the general
principles were similar. Briefly, for genome sequencing pooled
libraries of patient DNA were sequenced and the resulting files
were aligned using the GRCh37 version of the human genome.
Table 1 Summary of clinical phenotype of probands 1–5.
Proband 1 Proband 2 Proband 3 Proband 4 Proband 5
Site of study SickKids, Toronto Leeds, England London, England Manchester, England Wroclaw, Poland
Sequencing type GS ES GS GS ES
Gender (age, years) F (19) F (33) M (47) M (32) F (24)
Ethnicity Barbados/Black and Greek South Asian South Asian South Asian Polish
Ocular diagnosis ARRP ARRP ARRP ARRP ARRP
Onset of symptoms Birth, photophobia 9 years, nyctalopia 25 years, nyctalopia 44 years, VF loss 18 years, VF loss 21 years
VA (LogMar) 0.4, 0.5 (13 years) 0.4, 0.4 (31 years) 0, 0.2 (13 years) NA 0.1, 0 (23 years)
OD, OS 0.6, 0.5 (19 years)
Color vision Absent NA NA NA Normal
ERG Nonrecordable (19 years) Reduced responsesa Reduced responsesa Reduced responsesa Reduced responses
(23 years)
GVF <10 degrees Constricteda Constricteda Constricteda Constricted
DYNC2H1 variants V1: c.12605_12606dup V3: c.9836C>G V3: c.9836C>G V3: c.9836C>G V4: c.7987A>C
p.Asp4203Trpfs*7 p.Ser3279* p.Ser3279* p.Ser3279* p.Thr2663Pro
V2: c.6632A>T homozygous V5: c.12716T>G
p.Glu2211Val p.Leu4239Argb
Normal LogMar VA is 0, legal blindness is 1.ARRP autosomal recessive retinitis pigmentosa, ERG electroretinogram, ES exome sequencing, GS genome sequencing, GVF
Goldmann visual field, OD right eye, OS left eye, VA visual acuity, VF visual field.
aReported.
bVariant has been previously reported in Schmidts et al.4 DYNC2H1 variants are reported according to NM_001080463.1.
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Different approaches and prediction tools were then used to
analyze the coding and noncoding sequence. Specifically, under
an autosomal recessive model and using control population
databases, the sequences were filtered for rare variants (<1%
minor allele frequency; MAF) that would be presumed
pathogenic. When possible variant segregation analysis was
done. Analysis of the exome used a similar approach for the
coding portion of the genome (Supplementary Methods).
Transcript detection and quantification
Quantification of proband 1 DYNC2H1 transcripts was
performed using MassARRAY (Agena Bioscience, San Diego,
PROBAND 4 (Manchester)
PROBAND 5 (Wroclaw)
Normal OCT
PROBAND 1 (Toronto)
V2/WT V1/WT
V1/V2V1/WTWT/WT
V5/WT V4/WT
V4/V5NA
V3/V3
V3/V3
NA
NA
V3/V3 NA
NA NA
PROBAND 2 (Leeds)
V3/V3 NA
NA NA NA
NA
PROBAND 3 (London)
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b
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CL
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CA, USA) genotyping of complementary DNA (cDNA)
reverse transcribed from patient fibroblast RNA.17 Briefly,
multiplex polymerase chain reaction (PCR) amplification of
the DYNC2H1 transcripts was followed by single-base
extension from primers directly flanking transcript-specific
single-nucleotide polymorphisms (SNPs) of interest. Primers
used are listed in Table S1. Results were generated by matrix-
assisted laser desorption/ionization–time of flight (MALDI-
TOF) mass spectrometry using Typer 4.0 software to identify
and quantify the nucleotide present in the sample at the
position of interest (Supplementary Methods).
Fibroblast ciliation assay
Proband 1–derived fibroblasts were used for immunofluores-
cence and analysis of cilia formation and function. Approxi-
mately 250,000 fibroblast cells were seeded on cleaned glass
coverslips in 12-well plates. Following standard protocols
detailed in the Supplementary Methods, serum starved cells
were fixed with ice cold methanol and primary antibodies for
IFT88, acetylated tubulin, and gamma tubulin were used for
immunofluorescence experiments. A spinning disk confocal
microscope (Zeiss, Oberkochen, Germany) was used for
imaging and IFT88 fluorescence intensity in cilia was
quantified manually using the sum intensity images in FIJI18
(Supplementary Methods).
Protein expression and purification
A H. sapiens cytoplasmic dynein-2 motor domain construct
containing an N-terminal SNAPf tag
19 was modified to make
V1 and V2 constructs. For V1, residues 4196–4201 were
changed to sequence WIALNL and residues 4202–4307
(inclusive) were deleted. For V2, residues 2160–2211 (inclusive)
in AAA2 were removed, corresponding to exon skipping in V2.
Variants were introduced using PCR with Q5 polymerase (New
England Biolabs, Ipswich, MA, USA). Dynein-2 constructs were
expressed in Spodoptera frugiperda (Sf9) insect cells (Thermo
Fisher Scientific, Waltham, MA, USA) using a baculovirus
system as previously described.19 Protein purifications were
performed at 4 °C. Proteins of interest were eluted by
resuspending the resin in TEV buffer, adding 20 μg TEV
protease, and incubating the reaction overnight on a roller.
TEV-cleaved proteins were separated from the resin using an
empty column (Supplementary Methods).
Microtubule gliding assays
Wild type (WT), V1, and V2 dynein-2 motor protein samples were
biotinylated for microtubule gliding assays via their N-terminal
SNAPf tag as described
19 (Supplementary Methods). V1 and V2
dynein-2 motor protein samples were immobilized on a coverslip
and fluorescently labeled microtubules and adenosine triphosphate
(ATP) were added. The immobilized motor domains propelled
the microtubules over the coverslip, and the velocity of microtubule
movement was quantified using total internal reflection fluores-
cence (TIRF) microscopy. As the velocity of microtubule move-
ment depends on dynein-2 concentration,19 all constructs were
normalized to a concentration of 1.6 nM. Microtubule gliding
velocities were calculated from kymographs generated in FIJI.18
Graphing was performed in Prism 5 (GraphPad).
Organoid assay
Fibroblasts BJ (ATCC® CRL-2522™) were cultured and
maintained in DMEM (Thermo Fisher Scientific, Waltham,
MA, USA) supplemented with 10% FBS (Labtec, Salzburg,
Austria), NEAA, and penicillin–streptomycin (Thermo Fisher
Scientific, Waltham, MA, USA). BJ induced pluripotent stem
cells (iPSCs) made previously20 were cultured and maintained
in Essential 8 Flex medium on plates coated with Geltrex
(Thermo Fisher Scientific, Waltham, MA, USA). BJ iPSCs
were differentiated to retinal organoids following the protocol
established by Zhong and collaborators.21
Fig. 1 Phenotype documentation and family pedigrees. (I) Proband 1: (a) Retinal imaging of the right and left eye showing some retinal pigmentary
changes and narrowing of the vessels. The optic nerve is overexposed and only had mild pallor. (b) Optical coherence tomography (OCT) centered on the
macula showing thinning of the outer retina. (c) MAIA™microperimetry showing decreased retinal sensitivity (black dots) despite decent vision. This leads to
fixation instability (turquoise blur from fixation points). (d) Chest X-ray, lateral and anterior–posterior (AP) view showing normal size and chest structure. The
pedigree shows segregation of the variants with the phenotype. Filled symbol: affected, arrow: proband. (II) Proband 2: (a) Wide field imaging of the retina
of proband 2 showing equatorial bone spiculing changes characteristic of retinitis pigmentosa (RP). (b) Wide field fundus autofluorescence showing a
hyperfluorescent area that represents the limits of the functional retina. (c) OCT imaging showing thinning of the outer retina. (d) Left: normal chest X-ray
(AP) and right: normal hand X-ray. This pedigree shows consanguinity with very little information about family members who were not available for
segregation analysis. Diamond shape symbol with no number: uncertain number of relatives, unknown gender. (III) Proband 3: (a) Fundus autofluorescence
showing retinal pigment epithelium atrophy (dark spots throughout). The right eye has a hyperfluorescent ring outlining viable retina. (b) Below is a retina
photograph showing attenuated vessels, a marker of photoreceptor degeneration. (c) The OCT shows retinal thinning. Pedigree of the family is also showing
an autosomal recessive inheritance pattern and consanguinity. This proband was genotyped through a large genome sequencing initiative, and family
members were not available for segregation analysis. Diamond shape symbol with number: number of children, unknown gender. (IV) Proband 4: (a) Wide
field fundus autofluorescence showing pigmentary changes and a hyperfluorescent ring larger than for proband 2 though they are the same age. This
suggests a larger field of vision. (b) OCT view showing thinning of the outer retina. The pedigree shows pseudodominant (autosomal recessive) inheritance,
seen in consanguineous families though consanguinity is not documented. The family was not available for segregation analysis. (V) Proband 5: (a) Imaging
of the retina showing retinal atrophy outside the central area (macula) but the vessels were not severely constricted. bone spicules were visible only in the
periphery (not shown). (b) OCT imaging showing thinning of the outer retina. c) Normal chest X-ray (AP view). The family pedigree is shown with
segregation of variants with the phenotype. (VI) Normal OCT showing the different layers of the retina. Important to this work is the outer retina, which
includes CL connecting cilia layer, ISL inner segment layer, OSL outer segment layer, RPE/BM retinal pigment epithelium/Bruch’s membrane, WT wild type.
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For validation of DYNC2H1 microexon expression, RNA
was extracted from cell lines and retinal organoids using the
RNeasy Micro Kit (Qiagen, Hilden, Germany) following the
manufacturer instructions. Then, 50 ng of RNA were
converted to cDNA by the Tetro cDNA Synthesis Kit
(Bioline, London, UK) and a mixture of oligo-dT and random
hexamer primers. Next, 2.5 ng of cDNA were used to detect
the DYNC2H1 gene isoforms. For control BJ-derived retinal
organoid cDNA, PCR amplicons for the DYNC2H1 retinal
isoform only differed by 21 bp. This caused formation of
nonspecific cDNA heteroduplex. For this reason, samples
were subjected to digestion by 3 units/sample of T7
Endonuclease I (New England BioLabs, Ipswich, MA, USA)
at 37 °C, 60 minutes prior to loading a 2.5% agarose gel for
visualization. Bands were excised and extracted from the gel
using the QIAquick Gel Extraction Kit (Qiagen, Hilden,
Germany) and sent for Sanger sequencing.
RESULTS
Through an international collaboration between Canada, the
UK, and European Retinal Disease Consortia (IRDC and
ERDC), we have identified five DYNC2H1 variants as
associated with five cases of nonsyndromic IRD from cohort
members in Canada, the UK, and Poland. Proband pheno-
types are summarized in Table 1, Fig. 1, and Supplementary
Results. Information about the variants found is summarized
in Tables S2–S6 and Figs. S1–S2.
Clinical evaluation
All probands were diagnosed with nonsyndromic retinitis
pigmentosa (RP), a variant of IRD (Table 1, Fig. 1 and
Supplementary Results). Probands had normal development,
cognition, height, weight, and X-rays (Fig. 1). Age at onset of
symptoms ranged from childhood to mid-40s (Table 1). The
changes in visual acuity were slowly progressive. Generalized
photoreceptor dysfunction was documented by visual fields
constriction and electroretinography (ERG), which showed
either nonrecordable or severely reduced responses. There
was no significant refractive error. When possible, retinal
examination identified the classical features of RP, i.e.,
spiculed pigment migration and arteriolar attenuation while
outer retinal degeneration was visualized by OCT and fundus
autofluorescence imaging (Fig. 1).
Identification of causative DYNC2H1 variants (V1–V5)
Genome sequencing of genomic DNA from probands 1, 3 and
4, and exome sequencing for probands 2 and 5 (Fig. S1,
Supplementary Methods, Tables S2 & S3) identified presumed
pathogenic variants, V1–V5, mapped to the motor domain of
the DYNC2H1 protein (Fig. S2).
In proband 1 (Greek/Barbados descent) from Canada, the
novel compound heterozygous DYNC2H1 variants (V1:
c.12605_12606dup, p.Asp4203Trpfs*7, NM_001080463.1;
V2: c.6632A>T, p.Glu2211Val, NM_001080463.1) were the
only variants from the genome sequencing that met defined
pathogenicity criteria (Supplementary Methods, Tables S2 &
S4, Fig. S1) and segregated with the disease phenotype in the
family. V1 was predicted to introduce a premature termina-
tion codon (PTC) yielding a protein lacking the C-terminal
106 amino acids. While V2 introduced a missense change, it
mapped to a splice site required for incorporation of exon 41
into the protein and it was predicted in silico that V2 would
cause the loss of the natural donor site of DYNC2H1 exon 41:
c.6633 NM_001080463.1 (Table S5).
Presumably unrelated probands 2, 3, and 4 were found to
have a novel homozygous PTC variant (V3: c.9836C>G, p.
Ser3279*, NM_001080463.1) in a microexon that is specific to
a noncanonical isoform of DYNC2H1 (NM_001080463.1).
Organoid data indicate that this noncanonical isoform is
predominant in the retina (Fig. 2). Probands 2, 3, and 4 were
of South Asian descent but from different parts of the UK
fibs iPSC 40 90 100 120 150 200 
retinal organoids (days)
*DYNC2H1
GAPDH
a
* retinal isoform
* Retinal microexon 64
Reference Sequence
canonical isoform
Exon 63 Exon 65b
c
40       60       80      100     150     200 
retinal organoids (days)
PAX6
VSX2
CRX
NRL
NR2E3
GAPDH
Fig. 2 Inclusion of DYNC2H1 retinal microexon in human retinal
organoid development. (a) Reverse-transcription polymerase chain
reaction (RT-PCR) showing the expression of DYNC2H1 in BJ fibroblasts
(fibs), induced pluripotent stem cells (iPSCs), and retinal organoids at 40,
90, 100, 120, 150, and 200 days of differentiation. The shorter PCR product
on the gel corresponds to the canonical DYNC2H1 transcript from exons 63
and 65. The longer amplicon (*) includes the retinal-specific microexon 64
(human exon ID GT_21385 on http://ascot.cs.jhu.edu/). (b) Sequencing
electropherograms of the canonical and retinal (*) isoforms with alignment
to the DYNC2H1 reference sequence. The retinal microexon is boxed in red.
(c) Retinal organoid differentiation was confirmed by RT-PCR for markers of
retinal differentiation (PAX6, VSX2, CRX, NRL, NR2E3) at 40, 60, 80, 100,
150, and 200 days of differentiation.
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(Leeds, Manchester, and London, respectively), and haplotype
analysis supported a founder effect for V3 in this population
(Table S6).
Proband 5 from Poland had compound heterozygous
variants (V4: c.7987A>C, p.Thr2663Pro, NM_001080463.1;
V5: c.12716T>G, p.Leu4239Arg, NM_001080463.1) that
segregated with the disease phenotype and were confirmed
to be in trans. The missense variants V4 and V5 were
predicted deleterious using in silico prediction tools available
(Fig. S2, Table S4). The region affected by V4 displays high
conservation, both on nucleotide (phyloP 7.29) and amino
acid (up to Hawaiian sea urchin) levels (Fig. S2), which
suggests its importance for the proper functioning of the
protein. Indeed, Thr2263 forms part of the AAA4 nucleotide-
binding pocket,22 and V4 (Thr2263Pro) is predicted to
perturb nucleotide binding at AAA4 (Fig. S2). V5 maps to a
β-sheet within the motor C-terminal domain (Fig. S2).
Substitution of a hydrophobic leucine residue for a charged
arginine residue within the β-sheet is likely to perturb the
folding and stability of the protein. V5 was previously
reported in HGMD (CM133150) in case of JATD, hence it
is not discussed further.
Other putative pathogenic variants from the five cases
were excluded based on established internal exclusion
criteria (Supplementary Results, Fig. S1). Novel DYNC2H1
variants were rare (MAF < 0.001%) or not present in the
Bravo23 or gnomAD24 population databases (Table S4). At
least two of the predictive pathogenicity programs used
predicted damaging scores for all V1–V5 (Table S4) and
the amino acids involved were conserved across species
(Fig. S2).
Functional validation of variants
Functional validation experiments were undertaken for V1–V3.
V1 introduces a PTC and V2 causes skipping of DYNC2H1
exon 41
Analysis of proband 1–derived fibroblast cDNA by PCR and
Sanger sequencing confirmed that V1 caused a transcript with
a PTC (transcript 1, Fig. 3). This PTC would yield DYNC2H1
protein lacking the 106 C-terminal amino acids. V2 caused
incomplete in-frame skipping of DYNC2H1 exon 41 (tran-
script 2b, Fig. 3), with only 13% of the normally spliced (NS),
but mutated, transcript still produced (transcript 2a, Fig. 3).
Skipping of exon 41 would yield DYNC2H1 protein lacking
52 amino acids in its AAA2 module. Using Agena
massARRAY genotyping, the relative abundance of each
transcript was determined to be 15% transcript 1, 13%
transcript 2a, and 72% transcript 2b (Fig. 3).
V1/V2 perturb dynein-2 motor function
The impact of V1 and V2 on dynein-2 motor function was
tested in vitro. Wild-type (WT) human dynein-2 motor domain
was purified,19 along with two constructs with amino acid
changes matching those caused by V1 and the V2 variant
lacking exon 41 (Supplementary Methods). The V1 and V2
constructs produced protein of the expected molecular weight
(Fig. 3). However, the yield of the variant proteins was
substantially lower compared with WT. The activity of the
variant proteins was assessed using an in vitro motility assay
(Fig. 3). The WT construct propelled microtubules at an average
speed of 135 nm/s (±56 nm/s). Both V1 and V2 showed severely
reduced motility, with average speeds of 24 nm/s (±24 nm/s) for
V2 and 12 nm/s (±9 nm/s) for V1 (Fig. 3). The proportion of
microtubules that underwent any movement was also lower for
V1 and V2. While 82% of microtubules were propelled by WT,
only 25% and 42% of microtubules were propelled by V1 and
V2, respectively. Overall, both proband 1 variants perturbed
dynein-2 motor function.
V1/V2 affect IFT88 transport in fibroblasts
Proband 1–derived fibroblasts showed abnormal IFT88
protein accumulation in ciliary axonemes, which supports
DYNC2H1 malfunction (Fig. 4). There was no difference in
cilia incidence (data not shown).
V3 is part of a retina-predominant microexon
The homozygous variant V3 is predicted to introduce a PTC
in an isoform-specific 21-bp in-frame microexon
(NM_001080463.1), which to date has only been described
in human retinal tissue RNAseq experiments.25 RT-PCR from
control retinal organoid cDNA at different stages of
differentiation showed that expression of the microexon
began at day 120, with expression increasing with organoid
maturity to become the dominant transcript (up to day 200),
correlating with photoreceptor differentiation. The microexon
was not detected in cDNA from dermal fibroblasts, iPSCs, or
in retinal organoids at 40, 90, or 100 days postdifferentiation
(Fig. 2a). Sequencing of the resulting bands confirmed the
larger product included the microexon (Fig. 2b). The
microexon encodes a 7–amino acid insertion within the
AAA5 module of DYNC2H1 (Fig. S2). The presence of a stop
codon in the microexon would produce a severely truncated
protein. The lack of a systemic phenotype in probands 2, 3,
and 4 despite the presence of a homozygous stop variant in
the microexon provides further support for the retinal
predominance of this isoform and suggests that the canonical
isoform (NM_001377.2), expressed elsewhere in the body, is
unaffected.
In summary, we have identified five variants in DYNC2H1
that cause nonsyndromic IRD, either because they only affect
a retina-predominant transcript or because they are hypo-
morphic, resulting in a milder phenotype.
DISCUSSION
This work reports the association of mutant dyneins and
DYNC2H1 variants as a cause of nonsyndromic IRD, an
important cause of blindness worldwide. This not only
highlights the new role of dyneins in IRD but also extends
the range of severity associated with pathogenic variants in
DYNC2H1 and shows how interpretation of rare variants in a
different phenotype requires thorough validation.
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Thus far, human biallelic pathogenic variants in DYNC2H1
have been associated exclusively with JATD or SRPs,
occasionally lethal conditions.4,26 JATD features include
various skeletal anomalies such as short ribs, narrow thorax,
various bone anomalies, renal or liver disease with only four
cases of associated early retinal degeneration.4–6 SRP is more
severe and often leads to early prenatal lethality.26 The
manifestation of JATD and SRP may present with varying
degrees of severity.4,26 Variability in disease presentation is
not fully understood but includes genetic influences.27,28 The
role of modifier alleles has been suggested in a case of SRP
type II with double heterozygous variants in DYNC2H1 and
NEK1.29 In addition to genetic influences, other possible
explanations for the variability in disease manifestation
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Fig. 3 Analysis of the different DYNC2H1 transcripts of proband 1. Sanger sequencing (a), Agena MassARRAY experiments (b), and in vitro
microtubule gliding assays (c–f) show that proband 1 variably expresses three DYNC2H1 transcripts with impaired in vitro microtubule gliding. Variants are
numbered according to the DYNC2H1 transcript NM_001080463.1. (a) The top right electropherogram shows that transcript 1 is expressed even though V1
(orange) causes a frameshift and premature termination codon (PTC) in exon 88 (brown). Top left and bottom electropherograms show that V2 (red) causes
incomplete in-frame exon skipping of exon 41 (blue), resulting in the expression of transcript 2a with V2 and transcript 2b missing exon 41. Exon 40: pink.
Exon 42: green. Rest of the DYNC2H1 exons and introns: black dashed lines. Location of transcript-specific identifier nucleotides used for Agena Mas-
sARRAY experiments: roman numerals. (b) MassARRAY shows product peaks for identifier nucleotides I–IV and shows that 2b is the dominant transcript.
Allelotype frequency= (peak allele 1 – peak area variance allele 1) / (peak allele 1 – area variance allele 1) + (peak allele 2 – area variance allele 2). (c) Sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) of purified wild type (WT), V2, and V1 dynein-2 motor domains. (d) Fluorescently labeled
(Alexa-488) microtubules (MTs) are added and translocated by dynein in the presence of adenosine triphosphate (ATP). The movement is monitored using
total internal reflection fluorescence (TIRF) microscopy. Time sequence of microtubule translocation by immobilized wild type, V2, and V1 dynein motor
domains at 1.6 nM input concentration. (e) Plot of microtubule gliding velocity. Lines show mean values (± s.d.). n= 312 microtubule gliding events (WT),
n= 157 (V2), n= 91 (V1). Experiments were carried out in duplicate with two different protein preparations. cDNA complementary DNA, mRNA messenger
RNA, SNP single-nucleotide polymorphism.
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include environmental influences, epigenetic factors, and
varying impact of variants on DYNC2H1 protein structure
and function.4,29 Retinal involvement in DYNC2H1 JATD and
SRP cases is rare, but since these ciliopathies can be quite
severe and some affected individuals die early, the retinal
involvement could be underestimated.4 The association of
nonsyndromic IRD with syndromic ciliopathy-related disease
genes is increasingly documented.30–32 Furthermore, variants
in more than 80 cilia-related genes have been associated with
nonsyndromic IRD.14,15,33 Some of the mechanisms through
which mutated syndromic ciliopathy genes lead to nonsyn-
dromic IRD include variants in amino acids uniquely
important for visual function, variants in retina-specific
transcripts, variants causing reduced expression of syndromic
ciliopathy genes, and enhanced aberrant splicing in
photoreceptors.31,32,34,35 Documented DYNC2H1 disease-
associated variants are spread throughout the length of the
gene.4 These variants may lead to impaired ciliary protein
localization, reduced motility, and decreased IFT.8,9 The four
novel pathogenic variants identified here all map within the
motor domain of dynein-2 and all variants fall on residues
conserved in vertebrates (Fig. S2).
The in vitro mobility assays indicate that both V1 and V2
variants perturb the motor function of dynein-2 (Fig. 3). This
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Fig. 4 Ciliated proband 1 fibroblasts accumulate IFT88 (green) in ciliary axonemes. (a) Wild-type (WT) (top) and proband 1 V1/V2 mutant (bottom)
fibroblasts are stained with acetylated alpha tubulin (cilia axonemes, red), gamma tubulin (basal body, red), and Hoescht (nuclei, blue). Scale bars are 18 µm.
Panels on the right show enlargements of boxed ciliary IFT88 staining. Scale bars are 2 µm for enlargements. (b) Boxplot represents the distribution of IFT88
fluorescence intensity in proband 1 V1/V2 mutant and WT fibroblast cells. Data points are overlaid onto the boxplot to highlight the overlapping
fluorescence intensity measurements in patient and WT cells. IFT88 fluorescence intensity was measured in 100 patient’s? and 100 WT cilia. ***P < 0.0001
(Student’s unpaired t-test).
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suggests that dynein-2 activity in proband 1 would be a fraction
of wild-type protein; however, the residual activity in most
tissues is evidently sufficient to prevent syndromic disease.
V2 affects the penultimate nucleotide of DYNC2H1 exon 41
and changes the existing AG 5’ donor splice site to TG.
Although V2 causes in-frame exon skipping, the translated
protein would be missing 52 amino acids from the AAA2
module of the motor domain. We showed that V2 leads to
incomplete aberrant splicing, and that the nonskipped (NS)
transcript (which still harbors V2) remains expressed at
approximately 13% (Fig. 3). This NS transcript may well
retain some function, as it would only contain one variant
(V2) that maps to a residue on the surface of the protein that
is not strictly conserved. Hence it would be less likely to affect
folding/function (Fig. S2). The level of NS transcript could be
sufficient to ensure DYNC2H1 function in most tissues, with
the exception of the retina, which is highly reliant on
functional IFT. Our work suggests the mobility of IFT88 is
impaired. (Fig. 4). IFT88 is critical for photoreceptor
formation and human variants in IFT88 have been associated
with photoreceptor degeneration.16,36,37 Another possible
explanation for the isolated retinal phenotype in proband 1
could be that V2 causes different proportions of transcripts in
the retina, resulting in even more aberrant splicing.
In this study, V3, a homozygous novel PTC variant, was
identified in three nonsyndromic probands. This variant was
detected in a noncanonical isoform, which includes a 21-bp
microexon and appears to have a founder effect in South
Asians in the UK. Based on RT-PCR from retinal organoids
and RNAseq data25 we hypothesized that that this affected
isoform could be the major isoform expressed in the
photoreceptors. The noncanonical isoform was not detected
in differentiated fibroblasts and was only detected in matured
retinal organoids from day 120 onward, which coincided with
photoreceptor differentiation. As the organoids matured
beyond 200 days, this noncanonical transcript became the
dominant transcript (Fig. 2). This isoform is not expressed in
any other body tissues according to expression data from
GTEx.38 This provides another example of a variant in a
retina-predominant transcript as a cause of nonsyndromic
disease, a phenomenon previously documented.20 It will be
interesting to investigate how this microexon affects
DYNC2H1 function and if it is tailored to a specific function
in photoreceptor retrograde IFT.
In contrast to V1-V3 variants, the V4 and V5 variants were
both missense, causing substitution of threonine 2663
(NM_001080463.1) with proline, and leucine 4239
(NM_001080463.1) for arginine, respectively. V4 was located
within the AAA4 module of DYNC2H1, proximal to a
nucleotide-binding site. While the variant itself has not been
reported previously, a nearby arginine residue (c.2662,
NM_001080463.1) has been found mutated in two instances
in SRP Majewski type and SRP type I (unpublished data,
ClinVar RCV000515850.1).29 The V4 residue displayed high
conservation, both at the nucleotide and amino acid level (Fig.
S2). For proband 5 no functional work could be done, but we
hypothesize a situation similar to proband 1 in that V4 could
represent a hypomorphic allele, although additional studies
would be needed to prove this. It is not known if V4 could
possibly affect a retina-specific isoform. V4 may be assumed
to be essential for the proper functioning of the protein as
proper nucleotide binding at AAA4 is thought to play an
important structural role in dynein-2.22 V4 is also immedi-
ately adjacent to one of the critical conserved nucleotide-
binding motifs in DYNC2H1.22 Substitution to a proline, a
radically different amino acid, is extremely likely to perturb
nucleotide binding at this site and hence perturb the activity
of the protein, as shown for similar variants in DYNC1H1.39
V5 occurs in the DYNC2H1 C-terminal tail domain. This
variant was reported in JATD and the leucine residue, as well
as thymine nucleotide, are highly conserved.4 The presumed
milder impact of these variants may explain the milder disease
course and later age of IRD onset (21 years old) for this
individual.
In summary, the biallelic DYNC2H1 variants are reported as
a cause of non syndromic IRD in five cases. These data result
from either reduced stability or function of DYNC2H1 or in
loss of a retina-predominant isoform to which the photo-
receptors are uniquely susceptible. Although IRD is a rare
feature of JATD, this report highlights the extreme variability
of ciliopathy-related phenotypes. Considering the tight
relationship of dynein with IFT, which is essential to
photoreceptor function, genes encoding dynein-2 should be
considered as candidates for the unsolved cases of IRD.
Variants in syndromic disease genes associated with non-
syndromic phenotypes are emerging. We highlight the
different proposed disease mechanisms for these nonsyndro-
mic cases: variants in retina-predominant isoforms, tissue-
specific mis-splicing, and hypomorphic alleles.
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